Healthy Skepticism Library item: 6899

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Lexchin J.
Re: the promotion of Atrovent (ipratropium bromide)
1999 Jun;

Abstract:

In Russia Boehringer Ingelheim is promoting Atrovent (ipratropium bromide) as the first choice in therapy in chronic bronchitis. The advertisement also fails to provide any safety information. The scientific literature does not support the use of Atrovent as first-line therapy.

Keywords:
*analysis/Russia/developed countries/Atrovent/ipratropium bromide/Boehringer Ingelheim/quality of information/safety & risk information/Medical Lobby for Appropriate Marketing/MaLAM/ETHICAL ISSUES IN PROMOTION: COMPANY STANDARDS/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPED COUNTRIES